bladder urothelial carcinoma (Disease)

Synonyms:bladder transitional cell carcinoma, transitional cell carcinoma of bladder, urinary bladder urothelial carcinoma, urothelial bladder carcinoma

Id:DOID:4006

Description:A bladder carcinoma that has_material_basis_in transitional cells located_in the lining of the bladder.

Results found

Linked to

	Label	Description
	L1000 LINCS DCIC MOAR012 BC3C 24H P05 calmidazolium 3.33uM.tsv.gz File (Entity type)	A 84.4 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 MOAR008 BC3C 24H C01 testosterone 10uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 ASG002 BC3C 24H O02 crizotinib 1.11uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 MOAR012 BC3C 24H L11 tetrandrine 3.33uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC MOAR012 CAL29 24H F22 atizoram 10uM.tsv.gz File (Entity type)	A 127 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project
	L1000 LINCS DCIC MOAR012 CAL29 24H K11 DMSO.tsv.gz File (Entity type)	A 127 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 ASG002 CAL29 24H A10 taselisib 10uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 ASG002 BC3C 24H D15 R-547 0.12uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project
	L1000 LINCS DCIC ASG002 CAL29 24H O11 raloxifene 1.11uM.tsv.gz File (Entity type)	A 84.4 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project
	L1000 LINCS DCIC 2021 ASG002 BC3C 24H K10 bortezomib 20uM Biosample (Entity type)	A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC MOAR012 BC3C 24H P05 calmidazolium 3.33uM.tsv.gz

File (Entity type)

A 84.4 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 MOAR008 BC3C 24H C01 testosterone 10uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 ASG002 BC3C 24H O02 crizotinib 1.11uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 MOAR012 BC3C 24H L11 tetrandrine 3.33uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC MOAR012 CAL29 24H F22 atizoram 10uM.tsv.gz

File (Entity type)

A 127 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project

L1000 LINCS DCIC MOAR012 CAL29 24H K11 DMSO.tsv.gz

File (Entity type)

A 127 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 ASG002 CAL29 24H A10 taselisib 10uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 ASG002 BC3C 24H D15 R-547 0.12uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

L1000 LINCS DCIC ASG002 CAL29 24H O11 raloxifene 1.11uM.tsv.gz

File (Entity type)

A 84.4 KB file from LINCS produced from OBI:0002965 as part of the LINCS 2021 project

L1000 LINCS DCIC 2021 ASG002 BC3C 24H K10 bortezomib 20uM

Biosample (Entity type)

A biosample from LINCS produced as part of the LINCS 2021 project

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.